Despite the two price cuts that were previously notified from the ex officio adjustment and expiry of the premium pricing application period, the price of the 4 strengths of Bayer Korea’s Xarelto tab. products will continue to be maintained as is for the time being.

The company, which filed a suit against the government regarding the price cut, also requested for a suspension of execution of the price cut during the trial period, which the court accepted.

On the 2nd, the 11th division of the Seoul High Court ordered the suspension of execution of Xarelto’s price cut until the 30th day from the date of the judgment made for the case the company filed against the Ministry of Health and Welfa